Vorinostat [clinicaltrials_resource:fa0d853e53294044365a799a7ec4043e]
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy [clinicaltrials:NCT00005634]Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer [clinicaltrials:NCT00045006]Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) [clinicaltrials:NCT00091559]An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) [clinicaltrials:NCT00097929]clinicaltrials:NCT00106626A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) [clinicaltrials:NCT00109109]clinicaltrials:NCT00111813clinicaltrials:NCT00121225Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors [clinicaltrials:NCT00121277]A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) [clinicaltrials:NCT00126451]clinicaltrials:NCT00127101A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Solid Tumors (0683-029)(COMPLETED) [clinicaltrials:NCT00127127]A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) [clinicaltrials:NCT00127140]Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) [clinicaltrials:NCT00128102]clinicaltrials:NCT00132002clinicaltrials:NCT00132028Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer [clinicaltrials:NCT00132067]clinicaltrials:NCT00134043Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors [clinicaltrials:NCT00138177]clinicaltrials:NCT00138203Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia [clinicaltrials:NCT00217412]Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors [clinicaltrials:NCT00227513]clinicaltrials:NCT00238303Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors [clinicaltrials:NCT00243100]clinicaltrials:NCT00251589Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [clinicaltrials:NCT00253630]clinicaltrials:NCT00258349clinicaltrials:NCT00262834Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas [clinicaltrials:NCT00268385]Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00275080]Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia [clinicaltrials:NCT00278330]clinicaltrials:NCT00278395Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors [clinicaltrials:NCT00287937]clinicaltrials:NCT00305773Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00310024]Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00324480]Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00324740]Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer [clinicaltrials:NCT00324870]clinicaltrials:NCT00330161Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes [clinicaltrials:NCT00331513]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Vorinostat [clinicaltrials_resource:fa0d853e53294044365a799a7ec4043e]
Bio2RDF identifier
fa0d853e53294044365a799a7ec4043e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fa0d853e53294044365a799a7ec4043e
identifier
clinicaltrials_resource:fa0d853e53294044365a799a7ec4043e
title
Vorinostat
@en
type
label
Vorinostat [clinicaltrials_resource:fa0d853e53294044365a799a7ec4043e]
@en